ly3493269
Peptideexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 10, 2020 (NCT04178733)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
GIP agonist
GLP1R agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05794243 | Phase 1 | Mar 23, 2023 | Eli Lilly |
| NCT04682106 | Phase 1 | Dec 18, 2020 | Eli Lilly |
| NCT04498390 | Phase 1 | Sep 3, 2020 | Eli Lilly |
| NCT04515576 | Phase 1 | Aug 25, 2020 | Eli Lilly |
| NCT04178733 | Phase 1 | Jan 10, 2020 | Eli Lilly |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 5 | 5 | 1 | 2020 |
1 organizations
Page 1 / 1